Delgocitinib乳膏在轻至重度特应性皮炎成人中显示剂量依赖性疗效:8周随机IIb期试验结果
这项双盲、乳膏基质对照的IIb期试验将251例轻至重度特应性皮炎成人随机分配至Delgocitinib乳膏1、3、8、20 mg/g或基质组,每日两次用药8周。主要终点EASI评分变化呈剂量依赖性,各剂量组均优于基质组(P<0.05);vIGA-AD治疗成功率和EASI-75亦呈剂量依赖性提高;安全性良好。
要点
- Delgocitinib乳膏各剂量(1–20 mg/g)在8周时EASI改善均显著优于基质。
- 20 mg/g组vIGA-AD治疗成功率48.0%、EASI-75达66.0%,为各剂量中最高。
- 不良事件发生率与基质相似,常见上呼吸道感染、AD、痤疮、头痛和用药部位瘙痒。
核心结论
- Delgocitinib乳膏在主要和次要终点上均以剂量依赖方式优于乳膏基质,且耐受性良好,未发现安全性问题。
研究设计与样本
- 双盲、乳膏基质对照的IIb期试验(NCT03725722),纳入轻至重度特应性皮炎成人,按1:1:1:1:1随机分配至Delgocitinib乳膏1、3、8、20 mg/g或基质组,每日两次用药8周。
- 共随机251例患者(Delgocitinib乳膏组n=201,乳膏基质组n=50)。
主要发现
- 第8周EASI评分较基线变化:1 mg/g组-5.0、3 mg/g组-4.9、8 mg/g组-5.8、20 mg/g组-7.6,均P<0.05 vs 基质组-1.9。
- 第8周vIGA-AD治疗成功率:1 mg/g组18.4%、3 mg/g组29.2%、8 mg/g组30.0%、20 mg/g组48.0%,基质组10.4%。
- 第8周EASI-75:1 mg/g组40.8%、3 mg/g组43.8%、8 mg/g组56.0%、20 mg/g组66.0%,基质组20.8%。
- 不良事件发生率:Delgocitinib乳膏组44.5%,基质组56.0%;最常见(任一治疗组≥5.0%)为上呼吸道感染、AD、痤疮、头痛和用药部位瘙痒。
关键数值与推荐
- 主要终点为第8周EASI较基线变化;关键次要终点包括第8周vIGA-AD治疗成功(评分0或1且较基线改善≥2级)和EASI-75(EASI较基线改善≥75%)。
临床怎么用
- 对于轻至重度特应性皮炎成人,Delgocitinib乳膏每日两次外用8周可剂量依赖性改善皮损严重度,20 mg/g组疗效数值最高且安全性可接受。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Delgocitinib is a topical, pan-Janus kinase (JAK) inhibitor that targets all four members of the JAK family. In patients with atopic dermatitis (AD), delgocitinib ointment 0.5% resulted in improved efficacy compared with vehicle ointment and a favourable safety profile. OBJECTIVES: This double-blind, cream vehicle-controlled Phase IIb trial (NCT03725722) investigated the dose-response relationship, efficacy, and safety of delgocitinib cream in adults with mild to severe AD. METHODS: Adults with mild to severe AD were randomised 1:1:1:1:1 to delgocitinib cream 1, 3, 8, 20 mg/g or cream vehicle. Delgocitinib cream or cream vehicle were applied twice daily on the areas affected by AD for 8 weeks. The primary endpoint was change from baseline to week 8 in Eczema Area and Severity Index (EASI). Exploratory key secondary endpoints included Validated Investigator's Global Assessment for AD treatment success (vIGA-AD TS; defined as score of 0 [clear] or 1 [almost clear] with a ≥2-step improvement from baseline to week 8) and EASI-75 (≥75% improvement in EASI from baseline) at week 8. Safety was assessed throughout. RESULTS: Overall, 251 patients were randomised (delgocitinib cream groups: n=201; cream vehicle: n=50). At week 8, treatment with delgocitinib cream resulted in dose-dependent change in EASI scores from baseline versus cream vehicle (1 mg/g: -5.0; 3 mg/g: -4.9; 8 mg/g: -5.8; 20 mg/g: -7.6; all P<0.05 vs cream vehicle [-1.9]). A greater proportion of delgocitinib cream-treated patients achieved vIGA-AD TS (1 mg/g: 18.4%; 3 mg/g: 29.2%; 8 mg/g: 30.0%; 20 mg/g: 48.0%) than those in the cream vehicle group (10.4%) at week 8. EASI-75 was seen in 40.8% (1 mg/g), 43.8% (3 mg/g), 56.0% (8 mg/g) and 66.0% (20 mg/g) and 20.8% (cream vehicle) of patients at week 8. The incidence of adverse events was similar with delgocitinib cream (44.5%) and cream vehicle (56.0%), with most frequently reported adverse events (≥5.0% in any treatment group) being upper respiratory tract infection, AD, acne, headache, and application site pruritus. CONCLUSIONS: Treatment with delgocitinib cream was more effective than cream vehicle in a dose-response manner for the primary and secondary endpoints. Delgocitinib cream was well tolerated and no safety concerns were identified.
引用
- Silverberg JI, Beck LA, Gooderham M, et al. Delgocitinib cream formulation demonstrates a dose-dependent response in adults with mild to severe atopic dermatitis: results from an 8-week randomised Phase IIb trial. Br J Dermatol. 2026. PMID: 42483929. doi:10.1093/bjd/ljag296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。